<DOC>
	<DOCNO>NCT01124136</DOCNO>
	<brief_summary>The purpose study study use neurostimulation chronic advance refractory heart failure . The study determine safe use neurostimulation patient chronic advanced refractory heart failure also determine initial observation regard potential effect heart function quality life . The investigator hypothesis study show safe positive effect neurostimulation heart failure patient .</brief_summary>
	<brief_title>Neurostimulation Spinal Nerves That Affect Heart</brief_title>
	<detailed_description>Protocol Summary Title EVALUATION OF THE SAFETY OF NEUROSTIMULATION IN PATIENTS WITH SYMPTOMATIC HEART FAILURE FEASIBILTIY STUDY Description A feasibility trial use neurostimulation chronic advance refractory heart failure . Objective To determine safety neurostimulation patient chronic advanced refractory heart failure generate initial observation regard potential effect ventricular function quality life . Design The trial randomize double blind crossover feasibility trial 2 week 1,2,3,4,5,6,7 month clinical follow-up . After device implantation , patient enrol trial randomly assign device program deliver impulse , active , device program deliver impulse , inactive , 3 month . After 3 month initial phase , device inactivate 4 week washout period convene . At end washout period , patient inactive initial phase crossover active similarly patient active initial phase crossover inactive . Patient Population Patients non-ischemic ischemic cardiomyopathy length illness least 6 month meet inclusion exclusion criterion . Enrollment Enrollment total 10 intent-to-treat patient Investigational Sites Up 2 investigational site US Data Collection Data collection obtain three category : marker cardiovascular safety , marker device-device interaction marker efficacy .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Inclusion 1 . Male female ≥18 year ; 2 . Chronic heart failure NYHA class IIIIV ischemic nonischemic etiology ; 3 . Screening Left ventricular Ejection Fraction ( LVEF ) ≤ 30 % measure baseline echocardiography ; 4 . Screening 6 minute walk test score le 450 meter measure baseline ; 5 . Hospitalization heart failure outpatient IV administration inotropic agent , human Bnatriuretic peptide IV diuretic within past 12 month ( stable least 2 week ) ; 6 . On standard optimal medical therapy CHF medical therapy . * 7 . No change active cardiac medication 1 week prior treatment ; 8 . Written informed consent . Patients current prior symptom heart failure reduce LVEF stable optimally uptitrated medical therapy recommend accord current guideline ( Circulation . 2005 ; 112 ( 12 ) : e154 ) standard care heart failure therapy United States . This minimally include ACEinhibitor ( ACEI ) stable dos 1 month prior enrollment , tolerate , beta blocker ( carvedilol , metoprolol succinate , bisoprolol ) 3 month prior enrollment , tolerate , stable uptitrated dose 1 month prior enrollment . This also include Angiotensin II Receptor Blocker ( ARB ) stable dos 1 month prior enrollment , tolerate , ACEI tolerate . Stable define 100 % increase 50 % decrease dose . If patient intolerant ACEI , ARB , beta blocker , document evidence must available . In intolerant ACEI ARB , combination therapy hydralazine oral nitrate consider . Therapeutic equivalence ACEI substitution allow within enrollment stability timeline . Aldosterone inhibitor therapy add NYHA Class III IV symptom occur standard therapy . If aldosterone inhibitor therapy administer Class II patient , must initiate optimized prior enrollment . Eplerenone require dosage stability 1 month prior enrollment . Diuretics may use necessary keep patient euvolemic . Exclusion 1 . Inability comply condition protocol ; 2 . Inability perform cardiopulmonary exercise test due mechanical physical limitation 3 . Presence transplant tissue organ LVAD ( expectation within next 12 month ) ; 4 . Planned AICD CRT within next 12 month unless AICD prescribe primary prevention 5 . Pacemaker dependent patient . 6 . Acute MI , CABG , PTCA , within past 3 month 7 . Chronic refractory angina peripheral vascular pain ; 8 . Valvular heart disease require repair replacement ; 9 . Need chronic intermittent inotropic therapy ; 10 . Malignancy : evidence disease within previous 5 year ; 11 . Known HIV infection immunodeficiency state ; 12 . Chronic active viral infection ( hepatitis B C ) ; 13 . Severe systemic infection : defined patient undergo treatment antibiotic ; 14 . Active myocarditis early postpartum cardiomyopathy ( within first 6months delivery ) ; 15 . Systemic corticosteroid , cytostatics immunosuppressive drug therapy ( cyclophosphamide , methotrexate , cyclosporine , azathioprine , etc . ) , DNA deplete cytotoxic drug take within 4 week prior study treatment ; 16 . Patient pregnant , childbearing potential use adequate contraceptive method , nursing . ; 17 . Patient schedule hospice care ; 18 . Any medical , social geographical factor , would make unlikely patient comply study procedure ( eg . Alcohol abuse , lack permanent residence , severe depression , disorientation , distant location history noncompliance ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>Neurostimulation</keyword>
</DOC>